Damien Botsen, Sylvie Chabaud, Hervé Perrier, Hanifa Ammarguellat, Véronique Jestin-Le-Tallec, Jonathan Olesinski, Clémence Toullec, Thomas Aparicio, Meher Ben Abdelghani, Christophe Borg, Olivier Bouche, Clélia Coutzac, Hervé Devaud, Frédéric Di Fiore, Olivier Dubreuil, Ludovic Evesque, Bruno Huguenin, Marie Muller, Pierre-Guillaume Poureau, Emilie Oularue, David Tougeron, Aziz Zaanan, Samy Ammari, Nicolas De Sousa Carvalho, Pierre Decazes, Christelle De La Fouchardiere
BACKGROUND: Trifluridine/tipiracil (FTD/TPI) is approved in third-line treatment of patients with advanced/metastatic gastric and gastroesophageal junction adenocarcinomas (aGA/GEJA). The association of oxaliplatin with FTD/TPI is promising and the combination of FTD/TPI + oxaliplatin + nivolumab has shown a predictable and manageable safety profile. AIMS: The aim is to evaluate the efficacy and safety of FTD/TPI plus oxaliplatin with or without nivolumab in patients, with HER2 negative aGA/GEJA, unfit for triplet chemotherapy (TFOX/mFLOT regimen), in the first-line metastatic setting in comparison with the standard of care FOLFOX with or without nivolumab...
May 17, 2024: Digestive and Liver Disease